Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development.
The trial evaluated Cobnefy as an add-on therapy to existing atypical antipsychotics in adults with uncontrolled schizophrenia symptoms, according to an April 22 news release from the drugmaker.
After six weeks, patients receiving Cobnefy, along with an atypical antipsychotic, saw a 14.3-point reduction in the positive and negative syndrome scale score, compared to a 12.2-point reduction in the placebo group. As a result, the 2.0 difference did not reach statistical significance.
Secondary endpoints also showed no significant statistical differences, including changes in personal and social performance scores and clinical impressions severity scores.
The company plans to do a complete evaluation and share results at a future medical conference, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
